ADC Therapeutics

ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ADC Therapeutics posts robust Q4 results, eyes pipeline expansion

ADC Therapeutics delivered strong financial results, bolstered by Zynlonta's sales growth and a healthy cash position.
Strategic decisions on pipeline programs and market access initiatives demonstrate a focus on long-term growth and profitability.
While facing challenges such as market access delays and community adoption hurdles, ADC Therapeutics remains poised for success with multiple growth opportunities ahead.

ADC Therapeutics accelerates pipeline progress and optimizes ZYNLONTA's potential

ADC Therapeutics is making strides in pipeline prioritization and operational efficiencies, focusing on ZYNLONTA's commercial success.
The company faces challenges in navigating market dynamics and implementing strategic changes while capitalizing on growth opportunities.
Opportunities lie in expanding trial sites, exploring potent combinations, and leveraging the new go-to-market model for enhanced performance.
Overall, ADC Therapeutics aims for sustained growth through strategic resource allocation and operational enhancements.

ADC Therapeutics reports revenue growth and strategic expansions in Q2

ADC Therapeutics showcased solid Q2 performance with revenue growth and strategic expansions.
While facing challenges in clinical trials and market dynamics, the company is leveraging strengths in portfolio investments and market positioning.
Opportunities lie in upcoming milestones, international expansions, and innovative sales strategies for sustained growth.

ADC Therapeutics reports mixed Q3 results, positive pipeline outlook

ADC Therapeutics faced challenges in ZYNLONTA sales but showcased positive pipeline updates and promising Cami trial results.
Management's focus on cost control and cash preservation aligns with maintaining financial stability until mid-2025.
Analysts' inquiries into commercial strategies and regulatory timelines reflect market interest and potential growth opportunities.
Overall, ADCT's performance highlights a mix of challenges, strengths, and opportunities in navigating the competitive landscape.

ADC Therapeutics reports robust earnings, eyes expansion in oncology market

ADC Therapeutics demonstrated strong financial performance and progress in clinical trials, positioning itself well for future growth. Strategic focus on key pipelines and real-world data strategies highlight a commitment to innovation.
While facing competition and evolving treatment landscapes, the company has opportunities to expand ZYNLONTA and leverage next-gen platforms. Ongoing partnership discussions and upcoming trial results offer avenues for advancement.
Challenges include market differentiation, safety data focus, and successful trial enrollment. Managing these hurdles while capitalizing on growth opportunities will be crucial for ADC Therapeutics' future success.

ADCT reports revenue growth and strategic advancements in Q1

ADCT's Q1 performance reflects revenue growth, cost management, and strategic investments in pipeline development and financial stability.
Strengths lie in ZYNLONTA's performance, successful fundraising, disciplined capital allocation, and diversified pipeline progress.
Challenges include market competition, net losses, regulatory considerations, and balancing expenses with revenue growth.
Opportunities arise from expanding into new indications, advancing therapeutic candidates, regulatory engagements, and solid tumor pipeline growth.

ADC Therapeutics achieves profitability driven by ZYNLONTA in hematology

ADC Therapeutics demonstrated strong financial performance with commercial profitability and cost management improvements.
The company's focus on hematology and advancements in product pipeline position them for future growth.
While facing challenges in sales variability and market competition, ADC Therapeutics has opportunities for expansion and differentiation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ADC Therapeutics' (ADCT) CEO Chris Martin on Q3 2020 Results - Earnings Call Transcript

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today reported financial results for the third quarter ended September 30, 2020 and provided recent business highlights. “The third quarter was one of tremendous execution as we prepare for

ADC Therapeutics Reports Third Quarter 2020 Financial Results and Provides Recent Business Highlights

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced that Chris Martin, Chief Executive Officer, will present a company overview at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 9:20 am ET. A live webca

ADC Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced that it will host a conference call and live webcast on Thursday, November 12, 2020 at 8:30 am ET to report financial results for the third quarter ended September 30, 2020 a

ADC Therapeutics to Host Third Quarter 2020 Financial Results Conference Call on November 12, 2020

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced that eight abstracts have been selected for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting, which is being held virtually from December 5-8, 2020

ADC Therapeutics Announces Eight Presentations on Data from its Next-Generation Antibody Drug Conjugates at the 62nd American Society of Hematology Annual Meeting

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced that the first patient has been dosed with camidanlumab tesirine (Cami, formerly ADCT-301) in combination with pembrolizumab, a checkpoint inhibitor, in an ongoing Phase 1b c

ADC Therapeutics Announces First Patient Dosed with Camidanlumab Tesirine (Cami) in Combination with Pembrolizumab in Ongoing Phase 1b Clinical Trial in Selected Solid Tumors

Genmab - ADR

Media Release Copenhagen, Denmark and Lausanne, Switzerland, October 30, 2020

Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients with hematological malignancies and solid tumors, announced today the underwriters in its recent upsized public offering of 6,000,000 common shares, which closed on September 28, 2020, have exercised in full their option to purchase an additional

ADC Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Common Shares

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients with hematological malignancies and solid tumors, announced today the pricing of an upsized public offering of 6,000,000 shares of its common shares at a price of $34.00 per share. The gross proceeds from the offering, before deducting underwriting

ADC Therapeutics Announces Pricing of Public Offering

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients with hematological malignancies and solid tumors, announced today the commencement of a proposed underwritten public offering of 5,500,000 shares of its common shares. Certain existing shareholders expect to grant the underwriters a 30-day option t

ADC Therapeutics Announces Proposed Public Offering

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for loncastuximab tesirine (Lonca) for the treatment of patients with r

ADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced the presentation of an on-demand e-poster titled “First-in-Human Study of Camidanlumab Tesirine (ADCT-301, Cami), an anti-CD25 Targeted Therapy in Patients with Advanced Soli

ADC Therapeutics Announces Presentation of Preliminary Findings from Phase 1b Clinical Trial of Camidanlumab Tesirine (Cami) in Advanced Solid Tumors at ESMO Virtual Congress 2020

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced that preclinical data related to camidanlumab tesirine (Cami, formerly ADCT-301) has been published in the Journal for ImmunoTherapy of Cancer, the online journal of the Soci

ADC Therapeutics Announces Publication Highlighting the Potential of Camidanlumab Tesirine (Cami) as a Novel Immuno-oncology Approach for Solid Tumor Cancers

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), today gave notice that Morgan Stanley & Co. LLC and BofA Securities, Inc.

ADC Therapeutics Gives Notice of Partial Waiver of Restrictions Pursuant to FINRA Rule 5131

ADC Therapeutics SA (ADCT) CEO Christopher Martin on Q2 2020 Results - Earnings Call Transcript

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today reported financial results for the second quarter ended June 30, 2020 and provided recent business highlights. “ADC Therapeutics progressed rapidly this past quarter, and we are contin

ADC Therapeutics Reports Second Quarter 2020 Financial Results and Provides Recent Business Highlights

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced that it will host a conference call and live webcast on Tuesday, August 18, 2020 at 8:30 am EDT to report financial results for the second quarter ended June 30, 2020 and pro

ADC Therapeutics to Report Second Quarter 2020 Financial Results on August 18, 2020

AMSTERDAM--(BUSINESS WIRE)--Synaffix B.V., a biotechnology company focused on enabling antibody-drug conjugates (ADCs) with superior therapeutic index based on its proprietary ADC technology platform, announces that ADC Therapeutics SA has expanded its existing collaboration to explore additional applications, including DAR1, of Synaffix’ site-specific conjugation technologies.

Synaffix Announces Expansion of Collaboration with ADC Therapeutics

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced that the first patient has been dosed in the pivotal Phase 2 portion of LOTIS 3, a Phase 1/2 clinical trial evaluating loncastuximab tesirine (Lonca, formerly ADCT-402) in com

ADC Therapeutics Announces First Patient Dosed in Pivotal Phase 2 Portion of LOTIS 3 Clinical Trial of Loncastuximab Tesirine (Lonca) in Combination With Ibrutinib

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE:ADCT), a clinical-stage oncology-focused biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology, today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami, formerly ADCT-301) in p

ADC Therapeutics Announces U.S. Food and Drug Administration Has Lifted Partial Clinical Hold on Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine

VIRGINIA BEACH, Va., June 30, 2020 /PRNewswire/ -- New Ventures Funds, a venture fund targeting investments in companies across healthcare and life sciences, is pleased to announce the IPO of its portfolio company, ADC Therapeutics (NYSE:ADCT). The company raised $267.6 million through...

New Ventures Portfolio Company, ADC Therapeutics, Completes $267 Million IPO

ADC Therapeutics S.A. ADCT, +59.10% shares rocketed 56% Friday in their trading debut, after the Swiss biotech's initial public offering priced above its proposed price range and underwriters increased the size of the deal.

News for ADC Therapeutics Stock (ADCT)